Financial terms of the agreement were not disclosed.
This is a transformative step for the company and will broaden its immunomodulation platform into oncology.
The licensed technology is a modified measles virus based on the viral genome sequence of the established measles vaccine strain, which has been used to immunize billions of people worldwide.
The measles virus itself has innate anti-cancer properties, for example, mediating tumor cell lysis, T cell activation and specific tumor cell targeting.
Furthermore, it can also be engineered to include a tumor killing payload, making it a major building block for an effective oncolytic virus immunotherapy.
Themis established a cGMP manufacturing process for its measles vector technology and built a broad pipeline with both proprietary and partnered infectious disease vaccine candidates.
The lead programme in Chikungunya is anticipated to enter Phase 3 development in the near- to medium-term.
Themis believes that this licensing deal with Max-Planck-Innovation GmbH will further expand its innovative technology platform to include novel oncolytic virus-based immunotherapy applications.
Themis is developing immunomodulation therapies for infectious diseases and cancer.
As a technology transfer organisation of the Max Planck Society, Max Planck Innovation is the link between industry and basic research.
Its interdisciplinary team provides consulting and support for scientists in evaluating inventions, applying for patents, and founding companies. 134 spin-off companies have emerged from the Max Planck Society, of which the majority was accompanied by Max-Planck-Innovation.
Founded in 1805, the University Hospital Tuebingen is one of the leading centres of German university medicine.
As one of 33 University Hospitals in Germany, it contributes to a combination of medicine, research, and teaching.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine